Related coverage linked through entity extraction aliases.
May 14, 2026
Biotech M&A is shifting toward late-stage CNS and oncology assets with human clinical validation. Oncotelic Therapeutics said it advanced global IP protection for OT-101 and CNS drug delivery.
Apr 25, 2026
Oncotelic Therapeutics said it was featured in an editorial on how advancing drug pipelines are driving biotech valuation. The company cited its oncology pipeline, AI-enabled platform and 45% stake in GMP Bio.
Apr 20, 2026
Oncotelic Therapeutics announced expanded international intellectual property coverage for OT-101 across neurology, oncology and CNS drug-delivery technologies. The company also highlighted biotech valuation trends tied to clinical progress and its 45% stake in GMP Bio.
Mar 13, 2026
The blood-brain barrier continues to block most treatments for glioblastoma and central nervous system diseases, with only 0.01% of biologic drugs reaching the brain. New intellectual property coverage and synthetic methods aim to address delivery challenges.
